Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

Item

http://www.wikidata.org/entity/Q39032909

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

@en

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

@nl

type

Item

label

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

@en

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

@nl

prefLabel

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

@en

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.

@nl

P1476

Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect

@en

P2093

Caroline Samer

http://www.w3.org/2001/XMLSchema#string

Jules Desmeules

http://www.w3.org/2001/XMLSchema#string

Kuntheavy Ing Lorenzini

http://www.w3.org/2001/XMLSchema#string

Youssef Daali

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban

Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.

Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.

P304

494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2016.00494

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Fontana

P577

2016-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28066243

http://www.w3.org/2001/XMLSchema#string

P932

5165251

http://www.w3.org/2001/XMLSchema#string